ResApp Health Ltd, an ASX-listed digital health company, has signed a deal with global health products manufacturer RB to develop a smartphone app for consumers.

In a disclosure, ResApp said the app will utilise the company’s cough-based algorithms to identify different respiratory conditions and provide recommended next steps.

Also Read: Respiri Inks Deal with Pharmacy Guild of Australia

ResApp and RB have agreed to exclusively work together to build and test a prototype app for consumers to self-assess, or assess with the assistance of a pharmacist, their respiratory symptoms.

The cmpany’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware.

Its regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care settings.

It also owns SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. –